Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $75,044 | 30 | 53.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,754 | 20 | 31.2% |
| Unspecified | $12,323 | 11 | 8.8% |
| Food and Beverage | $4,937 | 114 | 3.5% |
| Travel and Lodging | $3,259 | 12 | 2.3% |
| Honoraria | $900.00 | 1 | 0.6% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $49,420 | 69 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $40,252 | 17 | $0 (2024) |
| PFIZER INC. | $28,777 | 39 | $0 (2024) |
| Janssen Biotech, Inc. | $8,620 | 33 | $0 (2024) |
| Celgene Corporation | $3,564 | 6 | $0 (2024) |
| Grifols, S.A. | $3,278 | 4 | $0 (2018) |
| Lilly USA, LLC | $2,400 | 1 | $0 (2021) |
| Ferring Pharmaceuticals Inc. | $2,274 | 5 | $0 (2024) |
| Celltrion Healthcare Co., Ltd | $900.00 | 1 | $0 (2017) |
| Janssen Global Services, LLC | $425.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,708 | 43 | Takeda Pharmaceuticals U.S.A., Inc. ($38,437) |
| 2023 | $4,767 | 19 | AbbVie Inc. ($4,426) |
| 2022 | $14,848 | 35 | ABBVIE INC. ($12,287) |
| 2021 | $16,979 | 29 | PFIZER INC. ($12,594) |
| 2020 | $13,815 | 10 | AbbVie Inc. ($8,620) |
| 2019 | $4,043 | 11 | Janssen Biotech, Inc. ($1,562) |
| 2018 | $8,672 | 21 | Grifols, S.A. ($3,278) |
| 2017 | $11,386 | 20 | AbbVie, Inc. ($5,729) |
All Payment Transactions
188 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,612.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/05/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| 11/08/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| 10/30/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $698.52 | General |
| 10/30/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 10/30/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $96.25 | General |
| 10/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,711.25 | General |
| 10/15/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| 10/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $4.31 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/30/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: Immunology | ||||||
| 09/26/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $3.01 | General |
| Category: Immunology | ||||||
| 09/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $49.91 | General |
| Category: Immunology | ||||||
| 08/21/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: Immunology | ||||||
| 07/26/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Immunology | ||||||
| 07/25/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $9.20 | General |
| Category: Immunology | ||||||
| 07/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,486.00 | General |
| 07/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,486.00 | General |
| 07/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,582.00 | General |
| 07/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), PLENVU | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Gastroenterology | ||||||
| 06/27/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,030 | 8 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,180 | 2 |
| M15-991 | AbbVie, Inc. | $112.53 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 113 | 129 | $89,812 | $11,997 |
| 2022 | 4 | 101 | 121 | $72,782 | $11,225 |
| 2021 | 8 | 148 | 170 | $99,501 | $15,374 |
| 2020 | 5 | 88 | 95 | $48,187 | $6,381 |
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 52 | 68 | $28,072 | $4,528 | 16.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 28 | 28 | $38,696 | $3,622 | 9.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $13,396 | $2,208 | 16.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 16 | 16 | $9,648 | $1,640 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 64 | $23,746 | $4,552 | 19.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 24 | 24 | $30,144 | $3,301 | 11.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 19 | 22 | $11,566 | $2,512 | 21.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 11 | 11 | $7,326 | $859.68 | 11.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 39 | 47 | $17,115 | $3,539 | 20.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 18 | $9,258 | $2,148 | 23.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 16 | 16 | $20,720 | $2,147 | 10.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 24 | 24 | $13,419 | $2,020 | 15.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 17 | 17 | $9,316 | $1,835 | 19.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $10,638 | $1,464 | 13.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 23 | $8,655 | $1,331 | 15.4% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 12 | 12 | $10,380 | $889.97 | 8.6% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 16 | 16 | $21,372 | $2,047 | 9.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 33 | 35 | $11,683 | $1,587 | 13.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $6,548 | $1,278 | 19.5% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 14 | 14 | $4,430 | $755.62 | 17.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 13 | 18 | $4,154 | $714.21 | 17.2% |
About Dr. Benjamin Cohen, MD
Dr. Benjamin Cohen, MD is a Gastroenterology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1639339039.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Cohen, MD has received a total of $140,217 in payments from pharmaceutical and medical device companies, with $65,708 received in 2024. These payments were reported across 188 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($75,044).
As a Medicare-enrolled provider, Cohen has provided services to 450 Medicare beneficiaries, totaling 515 services with total Medicare billing of $44,976. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Cleveland, OH
- Active Since 06/10/2008
- Last Updated 04/08/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639339039
Products in Payments
- XELJANZ (Drug) $19,638
- HUMIRA (Biological) $10,313
- SKYRIZI (Biological) $10,243
- Humira (Biological) $6,111
- TREMFYA (Drug) $5,355
- VELSIPITY (Drug) $4,814
- ZEPOSIA (Drug) $3,564
- STELARA (Biological) $3,266
- RINVOQ (Biological) $2,534
- CLENPIQ (Drug) $2,257
- Inflectra (Biological) $900.00
- ENTYVIO (Biological) $146.22
- Skyrizi (Biological) $112.53
- Entyvio (Biological) $104.67
- XIFAXAN (Drug) $54.84
- AMJEVITA (Biological) $40.06
- CREON (Drug) $27.23
- DUPIXENT (Biological) $24.75
- Talicia (Drug) $23.86
- ADSTILADRIN (Biological) $16.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Cleveland
Pierre Gholam, Md, MD
Gastroenterology — Payments: $1.7M
Ronnie Fass, Md, MD
Gastroenterology — Payments: $308,587
Dr. Taha Qazi, M.d, M.D
Gastroenterology — Payments: $185,665
Amandeep Singh, Mbbs, MBBS
Gastroenterology — Payments: $111,838
Bo Shen, Md, MD
Gastroenterology — Payments: $103,946
Amitabh Chak, Md, MD
Gastroenterology — Payments: $90,197